Basic Flexeril Information

• INN (International Nonproprietary Name): Cyclobenzaprine.
• Brand Names Available In Australia: Not available — Not approved.
• ATC Code: M03BX08.
• Forms & Dosages: Tablets 5 mg and 10 mg; extended‑release capsules 15 mg and 30 mg; oral suspension formulations reported internationally.
• Manufacturers In Australia: Not specified — no registered Australian manufacturer; major international suppliers include Teva, Mylan, Sun Pharma and Apotex.
• Registration Status In Australia: Not available — Not approved by the TGA for supply in Australia.
• OTC / Rx Classification: Prescription only (Rx) in all listed countries; cyclobenzaprine is prescription‑only internationally.

Latest Research Highlights

Are muscle relaxants worth the risk for a short, painful episode of back or neck strain?

Recent systematic reviews from 2022–2025 report that centrally acting muscle relaxants provide modest, short‑term pain relief in acute musculoskeletal conditions but increase sedation and anticholinergic adverse effects.

Randomised trials are generally small and short (typically 7–21 days) and focus on acute low back strain or neck spasm.

Pooled results show small‑to‑moderate reductions in pain over the short term, with inconsistent benefit for functional recovery.

Pharmacokinetic studies confirm hepatic metabolism and notable anticholinergic activity, which supports caution in older adults and those with liver disease.

Australian surveillance and TGA case reports emphasise harms in older people, including sedation‑related falls and confusion in aged‑care settings.

Global pharmacovigilance has flagged rare cardiac arrhythmias and serotonin syndrome when cyclobenzaprine is combined with serotonergic drugs.

Real dosing data used in trials: cyclobenzaprine 5–10 mg three times daily, short courses of 2–3 weeks maximum.

Clinical Effectiveness In Australia

Are Australian prescribers relying on the same evidence as overseas clinicians?

Cyclobenzaprine is not approved in Australia and has no PBS listing, so local effectiveness is inferred from international trials and TGA adverse‑event monitoring.

When prescribed off‑label via private import or overseas prescription, expected outcomes follow global findings: modest short‑term pain reduction when used as part of multimodal care including analgesics and physiotherapy.

The absence of a registered product in Australia limits large real‑world datasets and formal PBS‑driven prescribing patterns.

TGA case reports have emphasised higher harm among frail older people and those taking multiple central nervous system depressants.

In telehealth and rural contexts, clinicians tend to favour alternatives with established Australian supply chains such as tizanidine, baclofen and diazepam.

Typical regimen used overseas and in import scenarios is short courses of 7–21 days, prescription‑only, and contraindicated after recent myocardial infarction or with concurrent MAOI use.

Indications And Expanded Uses

What is cyclobenzaprine actually used for overseas?

Internationally, cyclobenzaprine is indicated for short‑term relief of acute musculoskeletal pain associated with muscle spasm, typically for 7–21 days.

Off‑label uses reported in some clinics include adjunctive short‑term therapy for acute low back pain, neck strain and transient spasm control following orthopaedic injury.

Cyclobenzaprine is not indicated for spasticity from central nervous system disease such as cerebral palsy or multiple sclerosis.

Contraindications to note include recent myocardial infarction, cardiac conduction disturbance, heart failure, concurrent MAOI use and severe hepatic impairment.

• Approved Use: Short‑term relief of acute muscle spasm (where available internationally).
• Common Off‑Label: Acute low back pain adjunct, short problem‑focused spasm control.
• Not Indicated For: Chronic spasticity from CNS disorders, children.

• Off‑Label Prescribing Checklist For Australian Clinicians:
• Document clinical rationale and informed consent.
• Confirm alternatives listed on the PBS were considered.
• Arrange follow‑up and review within 48–72 hours if started remotely.

Composition And Brand Landscape

Which preparations exist overseas and what would an Australian clinician encounter when considering import?

The active ingredient is cyclobenzaprine (INN), classified under ATC M03BX08 as an other centrally acting muscle relaxant.

Common international brands include Flexeril, Amrix and Fexmid, plus multiple generics supplied by manufacturers such as Teva, Mylan, Sun Pharma and Apotex.

Available forms internationally are tablets (5 mg, 10 mg), extended‑release capsules (15 mg, 30 mg) and oral suspensions.

Contraindications And Special Precautions

Who should definitely not take cyclobenzaprine?

Absolute contraindications include recent myocardial infarction, cardiac conduction disturbances, heart failure, concurrent MAOI use within 14 days, severe liver impairment and known allergy to cyclobenzaprine.

Relative cautions apply to older adults, people with hepatic or renal impairment, those taking other CNS depressants and people with glaucoma or urinary retention.

Common side effects are drowsiness and dry mouth, while rare but serious events include arrhythmia and serotonin syndrome when combined with serotonergic medicines.

• Pharmacist Counselling Checklist:
• Confirm absence of absolute contraindications.
• Review all medicines for interactions, especially antidepressants, opioids and benzodiazepines.
• Advise about sedation and fall risk; recommend no driving until tolerance established.

Dosage Guidelines

How is cyclobenzaprine usually dosed and what to do if a dose is missed?

Standard adult dosing internationally is 5 mg three times daily, which may be increased to 10 mg three times daily in tolerated patients.

Extended‑release options where available are 15 mg or 30 mg once daily in some markets.

The maximum recommended duration is short‑term only, typically 7–21 days.

• Missed Dose: Take as soon as remembered, but skip if it is nearly time for the next dose; do not double doses.
• Overdose Signs: CNS depression, tachycardia, arrhythmias, seizures — seek emergency care immediately.

Interactions Overview

What drugs should never be mixed with cyclobenzaprine?

Concurrent MAOI use within 14 days is an absolute contraindication because of potentially severe reactions.

Cyclobenzaprine combined with serotonergic agents such as SSRIs, SNRIs or tramadol increases the risk of serotonin syndrome.

Co‑administration with other CNS depressants including opioids, benzodiazepines and alcohol potentiates sedation, respiratory depression and fall risk.

Anticholinergic additive effects can occur with tricyclic antidepressants, first‑generation antihistamines and certain antipsychotics.

Cultural Perceptions And Patient Habits

How do Australians view muscle relaxants and access to them?

Many patients in Australia are price‑sensitive and rely heavily on the PBS for affordable medicines.

Awareness of cyclobenzaprine is low because it is not approved locally, so conversations usually focus on PBS‑listed alternatives such as tizanidine, baclofen and diazepam.

Telehealth has increased requests for private prescriptions and importation of unregistered drugs, especially in rural areas, which raises follow‑up and safety concerns.

Online forums and patient groups commonly express a preference for short courses and non‑sedating options when work or driving is involved.

• Patient Attitudes: Prefer short courses, cautious about sedating drugs, interest in physiotherapy and exercise.
• Telehealth Behaviour: Rural patients may seek private overseas scripts or importation; pharmacists must confirm follow‑up plans.
• Rural Vs Urban: Urban pharmacies prioritise PBS items; rural pharmacists often provide more in‑depth counselling and local referral advice.

Availability And Pricing Patterns

Can you buy Flexeril in Australia and what are the cost implications?

Cyclobenzaprine is prescription‑only in most countries but is not approved or registered in Australia, and therefore has no PBS subsidy or registered supply through major chains.

Australians seeking cyclobenzaprine usually pursue private importation, overseas prescriptions or substitute with PBS‑listed alternatives; this increases cost and regulatory complexity.

In our online pharmacy, flexeril is available without a prescription, with discreet delivery to Australia in 5‑14 days.

Private importation costs vary by country, brand and formulation, and are typically higher than PBS‑subsidised alternatives.

Comparable Medicines And Preferences

What are the practical alternatives in Australia and how do they compare?

Common alternatives with established Australian supply include tizanidine, baclofen, methocarbamol (limited), diazepam and non‑drug approaches such as physiotherapy and NSAIDs.

Choice depends on indication — acute strain versus spasticity — plus comorbidities, interactions and PBS availability.

Frequently Asked Questions

Can I get Flexeril in Australia?

No registered product exists in Australia; cyclobenzaprine is not approved locally.

Is cyclobenzaprine safe for older people?

Elderly people have increased risk of sedation and anticholinergic effects; start low, or choose alternatives and monitor falls.

How long can I take cyclobenzaprine?

Short‑term only — typically 7–21 days; not indicated for chronic spasticity.

What if I’m taking antidepressants?

There is a risk of serotonin syndrome when combined with serotonergic antidepressants, and MAOI use is an absolute contraindication; consult the prescriber before combining.

• When To Seek Urgent Care:
• Severe drowsiness or inability to wake, breathing difficulties, chest pain or palpitations, new seizures — seek emergency help.
• Signs of serotonin syndrome such as agitation, fever, rapid heartbeat or rigidity — seek urgent medical review.

Guidelines For Proper Use

How should clinicians and pharmacists manage cyclobenzaprine use safely in Australian practice?

Because cyclobenzaprine is not TGA‑registered, document clinical rationale and informed consent for any private import or off‑label prescribing.

Prefer evidence‑based short courses of 7–21 days combined with physiotherapy and analgesia rather than standalone long‑term therapy.

Check for absolute contraindications including recent myocardial infarction and MAOI use, and review all medicines for interactions.

Pharmacists should counsel clearly on sedation, no alcohol, no driving until tolerance is established and the need for early follow‑up.

• Stepwise Counselling Checklist:
• Confirm contraindications and interacting medicines.
• Advise starting dose and maximum duration (7–21 days).
• Warn about sedation, anticholinergic effects and when to stop.
• Arrange review within 48–72 hours if initiated by telehealth.

Storage: keep in original packaging, store at 20–25°C and protect from moisture and light.

Delivery Across Australia